Detail akcie Madrigal Pharmctcls online

Business Summary: Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Madrigal Pharmaceuticals Inc revenues increased from $76.8M to $637.3M. Net loss decreased 43% to $229.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of less than 1% to $17M (expense).